
TCBPY
Healthcare · Biotechnology · $11,566 market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 9, 2025 | Time not confirmed | — | -40.36 | — |
| Nov 25, 2024 | Time not confirmed | — | -79.73 | — |
| Aug 28, 2024 | Time not confirmed | — | -121.13 | — |
| May 29, 2024 | Time not confirmed | — | -447.21 | — |
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, develops immunotherapy products based on its allogeneic gamma delta T cell platform in the United States. Its product pipeline comprises OmnImmune (TCB002), an allogeneic unmodified gamma-delta T cell therapy product which is in phase 2/3 clinical trial for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to…